Anika Therapeutics (ANIK) Cash from Operations Growth (5y) (2015 - 2026)
Anika Therapeutics (ANIK) Cash from Operations Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.78 Bn | 87.91 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.95 Bn | 32.20 Bn | 1.97 Bn |
| 3 | Zoetis | 32.50 Bn | 30.56 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.56 Bn | 23.49 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.01 Bn | 20.85 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - |
| 7 | Viatris | 20.41 Bn | 18.61 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.77 Bn | 16.45 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.66 Bn | 12.23 Bn | 785.00 Mn |
| 10 | Anika Therapeutics | 203.10 Mn | 136.31 Mn | 19.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.79% |
| Dec 31, 2025 | 12.38% |
| Sep 30, 2025 | 3.21% |
| Jun 30, 2025 | -15.47% |
| Mar 31, 2025 | -16.26% |
| Dec 31, 2024 | -34.40% |
| Sep 30, 2024 | -12.98% |
| Jun 30, 2024 | -17.03% |
| Mar 31, 2024 | -15.04% |
| Dec 31, 2023 | -18.33% |
| Sep 30, 2023 | -9.77% |
| Jun 30, 2023 | -30.98% |
| Mar 31, 2023 | -18.91% |
| Dec 31, 2022 | -41.43% |
| Sep 30, 2022 | -25.87% |
| Jun 30, 2022 | -13.21% |
| Mar 31, 2022 | -16.23% |
| Dec 31, 2021 | -5.93% |
| Sep 30, 2021 | -28.86% |
| Jun 30, 2021 | 44.83% |